Source: CureToday articles
“Don’t aspire to make a living. Let’s aspire to make a difference in the Mandarin/Cantonese-speaking community.”
Recent Content
- Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
- The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
- FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
- FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
- FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
- Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
- The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
- Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways
- Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
- What Should Patients with Multiple Myeloma Know After ASCO 2025?